Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.40 |
| ▸ | F13A1 | P00488 | 5/20 | 0.40 |
| ▸ | TGM1 | P22735 | 5/20 | 0.40 |
| ▸ | TGM6 | O95932 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427650 | 1.00 | TGM2 (0.40) | TGM2F13A1TGM1TGM6CPB1 | |
| SCHEMBL4412540 | 0.91 | ALDH1A1 (0.41) | CPB1ALDH1A1GAATSHRKDM1A | |
| SCHEMBL4412545 | 0.91 | ALDH1A1 (0.41) | CPB1ALDH1A1GAATSHRKDM1A | |
| SCHEMBL2994264 | 0.89 | CPB1 (0.38) | TGM2F13A1TGM1CPB1ALDH1A1 | |
| SCHEMBL2994272 | 0.89 | CPB1 (0.38) | TGM2F13A1TGM1CPB1ALDH1A1 | |
| SCHEMBL2994267 | 0.89 | CPB1 (0.38) | TGM2F13A1TGM1CPB1ALDH1A1 | |
| SCHEMBL5854171 | 0.87 | CCR2 (0.39) | CPB1ALDH1A1GAATSHRMMP13 | |
| SCHEMBL5854166 | 0.87 | CCR2 (0.39) | CPB1ALDH1A1GAATSHRMMP13 | |
| SCHEMBL5854162 | 0.87 | CCR2 (0.39) | CPB1ALDH1A1GAATSHRMMP13 | |
| SCHEMBL2993483 | 0.81 | ALDH1A1 (0.46) | CPB1ALDH1A1GAATSHRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696205-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | TGM2 3456/4885F13A1 628/4885TGM1 2919/4885 |
| US-20080108678-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | TGM2 3397/4885F13A1 604/4885TGM1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.